Introduction
Myeloablative chemotherapy followed by allogeneic stem cell transplantation has been widely used as curative treatment in hematological malignancies. The procedure was originally proposed as a means to escalate the dose of chemotherapy above the maximally tolerated myelotoxic dose and to restore hematopoiesis with the allogeneic stem cell graft. However, the myeloablative conditioning regimen frequently does not eradicate the malignant clone and the immune-mediated graft-versus-leukemia (GVL) effect is important to prevent relapse. 1, 2 The most direct demonstration of the GVL effect is the reinduction of CR by the infusion of donor lymphocytes in patients with leukemia who had relapsed after allogeneic stem cell transplantation. 3 Improvement in supportive care and graft-versus-host disease (GVHD) prophylaxis have cre-ated the possibility of treating older patients, but few transplantation centers consider patients older than 55 years because of conditioning therapy-related toxicity. 4 However, the median age of patients with acute myeloid leukemia (AML) as well as most other hematological neoplasms is above 60 years and the prognosis of elderly patients is very poor even when CR is achieved. Therefore, novel therapeutic options are warranted.
The purin analog fludarabine as immunosuppressive agent was effective for ameliorating graft take and reducing the incidence of GVHD in mouse bone marrow transplantation models. 5, 6 To use the GVL effect without paying the price of conventional myeloablative conditioning some investigators have developed fludarabine-containing less intense conditioning regimens leading to hematological donor-recipient chimeras. [7] [8] [9] [10] We performed a pilot trial to determine whether the combination of immunosuppressive and antileukemic drugs are sufficient to enable engraftment and control of leukemia until donor hematopoiesis and the GVL effect are established. Therefore, we used the combination of fludarabine and cyclophosphamide with idarubicin and etoposide within the FCIE protocol.
Methods

Patient eligibility
The following patients were eligible for the study: patients above 55 years of age with AML, acute lymphoblastic leukemia Philadelphia chromosome-positive (ALL Ph + ), and chronic myeloid leukemia (CML) in accelerated or blastic phase; patients р55 years of age who were not eligible for a conventional myeloablative conditioning because of concurrent medical condition. Patients required an HLA-identical or one-antigen-mismatched related donor. Eligibility required adequate renal and hepatic function, a normal cardiac ejection fraction, and informed consent of the patients and donors. The study was approved by the local Ethics Review Committee.
Stem cell collection
Donors received filgrastim at 10 g/kg body weight subcutaneously once a day starting day −4. Leukaphereses were performed starting at day 0 using conventional techniques for blood progenitor cell collection for at least 2 days or until more than 5 × 10 6 CD34 + cell/kg of recipients body weight were collected. Donor cells were transplanted at the day of collection without cryopreservation or further processing.
Bone marrow harvest was assigned for donors who collected less than 2.5 × 10 6 CD34 + cell/kg.
Chemotherapy and supportive care
All patients were treated according to the FCIE protocol which consisted of fludarabine 25 mg/m 2 /days day -7 to -3, cyclophosphamide 200 mg/m / day days −7 to −3, idarubicin 12 mg/m / day days −7 to −5, and etoposide 250 mg/m / day days −4 and −3. The allogeneic grafts were infused beginning at day 0. All patients were treated as inpatients. They received antibacterial and antifungal prophylaxis with ciprofloxacin 500 mg orally twice daily and amphotericin B suspension 6 ml four times daily. Broad-spectrum antibiotics were begun for temperature higher than 38.5°C or clinical signs of infection. The hemoglobin level was maintained at more than 8 g/dl and the platelet count at more than 20 × 10 9 /l with filtered and irradiated blood products.
GVHD prophylaxis
GVHD prophylaxis consisted of cyclosporine at a dose of 3 mg/kg/day intravenously beginning at day −1 and changed to oral as soon as possible and methotrexate at day +1 with 15 mg/m 2 and at days +3 and +6 with 10 mg/m 2 . Patients without signs of GVHD on day 50 had their cyclosporine tapered by 10% to 20% weekly. Patients developing GVHD received methylprednisolone at 2 mg/kg/day intravenously and tapered upon response as tolerated.
Study endpoints
The primary objectives of this study were toxicity and feasibility of achieving engraftment of allogeneic blood progenitor cells in older patients with acute and chronic leukemias receiving intensive but not myeloablative chemotherapy. Chimerism was determined by short tandem repeats using published techniques. 11 CR, partial remission (PR), refractory disease and relapse were defined according to standard criteria. 12 Probability of survival, as well as probability to reach a white blood cell count (WBC) greater than 1 × 10 9 /l and an unsupported platelet count greater than 20 × 10 9 /l and 50 × 10 9 /l after transplantation were calculated according to the method of Kaplan and Meier. 13 The median follow-up duration was calculated according to the method of Korn.
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Results
Patient and donor characteristics
From November 1997 to March 1999, 11 patients were included in our study. Patient and disease characteristics are summarized in Table 1 . The median age was 62 years (range 30 to 69 years). Nine patients had AML, with four in 1st CR (age: 59 to 69 years), two in 2nd CR (age: 59 years, 63 years), one in 2nd relapse with multiple nodules in liver and spleen of unknown etiology (age: 30 years), and two with refractory disease (age: 63 years, 64 years). One patient had CML in accelerated phase (AP) (age: 62 years), and one patient had ALL Ph + in 1st CR (age: 57 years). The median number of prior cycles of chemotherapy was three (range 2 to 6); the pretransplant therapies are summarized in Table 1 . The median donor age was 55 years (range 33 to 69 years); six donors were over the age of 55 years. All donors were full HLA-identical siblings and all were male. Donors received a median of 6 days of treatment with filgrastim, nine donors underwent two aphereses and two required three procedures, both being over the age of 55 years. The days of treatment with filgrastim and the apheresis procedure were well tolerated by all donors except for mild bone pain which was relieved by oral paracetamol. The median number of CD34 
Toxicity of the conditioning regimen
The chemotherapy with FCIE was well tolerated. Treatmentrelated complications are summarized in 
Hematological reconstitution and acute GVHD
The median time to reach a WBC of 1.0 × 10 9 /l was 17 days (range 13 to 29 days) and an unsupported platelet count of 20 × 10 9 /l and 50 × 10 9 /l was 18 days (range 10 to 34 days) and 20 days (range 10 to 40 days) after transplantation, respectively (Table 3 ). All patients needed platelet transfusions ( Table 2 ). The WBC after transplantation never fell below 0.1 × 10 9 /l and in seven patients remained above 0.2 × 10 9 /l. The WBC of two patients with refractory or relapsed AML fell below 0.1 × 10 9 /l directly before transplantation, but increased after transplantation and never dropped in the following days below 0.1 × 10 9 /l. Two patients developed acute GVHD, both limited to skin (grade I). GVHD responded promptly to therapy with corticosteroids.
Chimerism analysis, chronic GVHD and patient outcome
Chimerism, outcome and survival are summarized in Table 3 . Four patients were transplanted with active disease and three of them cleared their peripheral blood blasts (UPN 1, UPN 4,  UPN 11 ). However, in patient UPN 1 peripheral blasts reappeared 2 weeks after hematological reconstitution and therefore no chimerism analysis was performed. Patient UPN 9 with refractory AML showed no engraftment. Patient UPN 4 with AML in second relapse achieved a 3rd CR with 100% donor chimerism and clearance of all nodules in his liver. He relapsed at day 163, achieved a 4th CR with 100% donor chimerism after reinduction therapy with high-dose cytarabine and is in sustained 4th CR following a second allogeneic transplantation after conventional myeloablative conditioning. Patient UPN 11 with CML in accelerated phase achieved a second chronic phase with 50% donor chimerism, but relapsed and died at day 391. In all seven patients transplanted in CR, there was a 80-90% donor chimerism 30 to 45 days after transplantation. Three patients with AML transplanted in first or second CR (UPN 3, UPN 7, UPN 6) relapsed at day 68, 264 and 595 after transplantation, respectively. Patient UPN 3 and patient UPN 7 died during reinduction therapy and patient UPN 6 died shortly after diagnosis of CNS relapse. Patient UPN 10 with ALL Ph + engrafted with 90% donor hematopoiesis, relapsed at day 79 and achieved a 2nd CR after omission of immunosuppression with 100% donor hematopoiesis. He developed severe GVHD of the gut grade IV which responded to combination immunosuppressive therapy. The patient is alive in 2nd CR 660 days after transplantation with mild GVHD of the skin. Three patients with AML transplanted in 1st or 2nd CR (UPN 2 , UPN 5, UPN 8) are in sustained CR 19 to 31 months after transplantation. One had mild chronic GVHD of the skin grade I. One of them had suffered from an episode of severe GVHD of the skin after excessive sun exposure during her holidays, which responded promptly to corticosteroids. The median follow-up was 22 months with an estimated overall survival of 44% at this time point (95% confidence interval: 13 to 74%).
Discussion
Despite modern combination chemotherapy the prognosis of patients with AML above the age of 60 years is dismal. [15] [16] [17] Besides comorbidity this is due to unfavorable biological characteristics of the leukemias such as high expression of the multidrug resistance protein 1, 18 high incidence of unfavorable chromosomal aberrations 19, 20 and high incidence of a myelodysplastic phase before developing AML. 21 Conventional myeloablative conditioning therapy followed by allogeneic stem cell transplantation can result in long-term disease-free survival in patients with advanced or refractory leukemias. 22, 23 In patients up to the age of 55 years with cytogenetically defined high risk AML, allogeneic transplantation may improve survival compared to conventional consolidation treatment or high-dose chemotherapy followed by autologous transplantation. 24, 25 Therefore, it seems reasonable to introduce the concept of allogeneic transplantation for the treatment of acute leukemias in the elderly. However, conventional myeloablative conditioning therapy followed by allogeneic stem cell transplantation is associated with a substantial treatment-related mortality (TRM) increasing with age. 26, 27 To reduce TRM nonmyeloablative conditioning regimens were introduced. A number of regimens were published which vary significantly in dose intensity. 28 Since the GVL effect alone may not be sufficient to control acute leukemias of the elderly, we designed a protocol in which immunosuppressive and antileukemic drugs were combined for nonmyeloablative conditioning. For immunosuppression we used the combination of fludarabine and cyclophosphamide. The combination of the purin analog fludarabine, which produces lymphocytopenia and substantial immunosuppression, 29, 30 and cyclophosphamide used in conventional myeloablative conditioning was shown to be very effective after non-myeloablative conditioning in enabling engraftment of donor hematopoietic stem cells and subsequent mixed donor/recipient chimeras. 9, 10 As antileukemic components we used the combination of idarubicin and etoposide, which is part of the consolidation treatment in our ongoing protocol for elderly patients with AML. 31 In our pilot study we treated 11 patients with high risk features for toxicity that prohibited the use of conventional highdose conditioning therapy. Ten of these patients were older than 55 years of age. Four patients had refractory disease, two of them with poor performance status. Despite these features the nonhematological toxicity was relatively mild.
Nine of 11 patients showed donor cell engraftment. Patients who failed to engraft recovered with autologous hematopoiesis. None of the patients had a WBC below 0.1 × 10 9 /l after transplantation and in seven patients the WBC never fell below 0.2 × 10 9 /l. This likely contributed to the low incidence of infectious complications in our series. The hematological recovery was within the range of published data using myeloablative conditioning and GVHD prophylaxis with methotrexate and cyclosporine. [32] [33] [34] The incidence of acute GVHD was low and in the two patients in whom acute GVHD occurred it was mild. This may reflect the reduced tissue injury especially of the gastrointestinal tract produced by the FCIE regimen compared to conventional myeloablative conditioning. After a median follow-up period of 22 months chronic GVHD was not a significant problem. Two episodes of severe extended GVHD occurred, one after excessive sun exposure responding well to corticosteroid treatment, and one after discontinuation of immunosuppression for treating relapse of ALL.
The clinical outcome was best in patients transplanted in CR of their disease. Of the seven patients transplanted in CR, three are in 1st continuous CR and one in 2nd continuous CR. In contrast, outcome was poor in patients transplanted with relapsed or refractory leukemia. None of the patients with refractory leukemia achieved CR. This is in line with another series of patients with refractory AML/MDS where only a minority of patients achieved a continuous CR after nonmyeloablative therapy. 7 The only patient younger than 55 years in our study with 2nd relapse of AML achieved a 3rd CR and major improvement of his clinical condition. In accordance with the report from Xun et al, 35 this shows that nonmyeloablative conditioning in younger patients not qualifying for myeloablative therapy because of concomitant medical illness can be an alternative to conventional myeloablative conditioning regimens.
In summary, this study shows that the combination of immunosuppressive and antileukemic drugs followed by allogeneic peripheral stem cell transplantation is feasible in elderly or debilitated patients with leukemia resulting in engraftment of donor hematopoietic cells. In contrast to chronic hematological neoplasms like chronic lymphocytic and chronic myeloid leukemia, dose intensification of the conditioning regimen before allogeneic transplantation with rhenium 188-labeled anti-CD66 monoclonal antibody seems to be beneficial in high risk acute leukemias. 36 This concept of myeloablation without the risk of excessive organ toxicity is especially attractive for elderly patients. Apart from the conditioning therapy the introduction of pre-emptive donor lymphocyte infusion may be crucial for future trials for maintaining complete remission in acute leukemias.
